Immunoengineering, which has been beneficial to other medical specialties, could be used in the infectious diseases field to ...

The "Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biopharmaceutical ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Thank you for standing by. And welcome to Invivyd’s First Quarter ...

Creative Biolabs upgrades its therapeutic antibody and protein development platform, with enhanced capabilities in endotoxin ...

Luton, Bedfordshire, United Kingdom, May 15, 2025 (GLOBE NEWSWIRE) -- The global medical bioreactor market is valued at approximately $4.1 billion in 2024 and is projected to reach around $7.2 billion ...

Current setbacks cannot prevent gene-editing companies from advancing closer to “one-and-done” cures and new products.

On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respirato ...

On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in ...

Total Operating Expenses: Total operating expenses were $42.9 million for the first quarter of 2025, including research and ...

Chugai Pharma seeks Japanese additional indication approval for Tecentriq to treat thymic carcinoma: Tokyo Thursday, May 15, 2025, 12:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd., ...

Cancer is cruel. It doesn’t care that you’re only 37, that you're the mother of a little girl who is your entire world. So Elissa vowed to fight.